Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects

Annals of Hematology

Volumn 89, Issue SUPPL. 1, 2010, Pages

  Jawa, Vibha ^a   Hokom, Martha ^a   Hu, Zheng ^a   El Abaadi, Naglaa ^a   Zhuang, Yao ^a   Berger, Dietmar ^a   Gupta, Shalini ^a   Swanson, Steven J ^a   Chirmule, Narendra ^a  

^a AMGEN INC   (United States)

Author keywords

Immune thrombocytopenic purpura (ITP); Immunogenicity; Platelet; Romiplostim; TPO

Indexed keywords

NEUTRALIZING ANTIBODY; PLACEBO; ROMIPLOSTIM; ANTIBODY; FC RECEPTOR; HYBRID PROTEIN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGENICITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIDE EFFECT; SURFACE PLASMON RESONANCE; AGONISTS; ANTIBODY PRODUCTION; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; ISOLATION AND PURIFICATION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

ANTIBODIES; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; CLINICAL TRIALS AS TOPIC; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN;

EID: 77955641872     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0908-2     Document Type: Article

References (26)

1. J Bussel D Kuter J George 2006 Romiplostim, a thrombopoiesis-stimulating protein, for chronic ITP N Engl J Med 355 1672 1681 10.1056/NEJMoa054626 1:CAS:528:DC%2BD28XhtFWgsrnO 17050891
2. D Kuter 2007 New thrombopoietic growth factors Blood 109 4607 4616 10.1182/blood-2006-10-019315 1:CAS:528:DC%2BD2sXmt1Ogt7g%3D 17289815
3. L Bottiger B Westerholm 1972 Thrombocytopenia. Incidence and aetiology Acta Med Scand 191 535 540 1:STN:280:DyaE383hslShuw%3D%3D 5064530
4. J Kelton S Gibbons 1982 Autoimmune platelet destruction: idiopathic thrombocytopenic purpura Semin Thromb Hemost 8 83 104 10.1055/s-2007-1005045 1:STN:280:DyaL387pvFCrsA%3D%3D 6210960
5. R McMillan 1981 Chronic idiopathic thrombocytopenic purpura N Engl J Med 304 1135 1147 1:STN:280:DyaL3M7nt1ynug%3D%3D 7012619
6. J Li C Yang X Yea 2001 Thrombocytopenia caused by the development of antibodies to thrombopoietin Blood 98 3241 3248 10.1182/blood.V98.12.3241 1:CAS:528:DC%2BD3MXovVSgs70%3D 11719360
7. J Crawford J Glaspy C Belani 1998 A randomized, placebo-controlled, blinded, dose-scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) with Filgrastim support in non-small cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy [abstract] Proc Am Soc Clin Oncol 17 285
8. R Basser E O'Flaherty M Green M Edmonds J Nichols 2002 Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor Blood 99 2599 2602 10.1182/blood.V99.7.2599 1:CAS:528:DC%2BD38XisFGhtr8%3D 11895799
9. G Shankar V Devanarayan L Amaravadi 2008 Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products J Pharm Biomed Anal 48 1267 1281 10.1016/j.jpba.2008.09. 020 1:CAS:528:DC%2BD1MXntlyisQ%3D%3D 18993008
10. S Gupta S Indelicato V Jethwa 2007 Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics J Immunol Methods 32 1 18 10.1016/j.jim.2006.12.004
11. E Koren H Smith E Shores 2008 Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology product J Immunol Methods 333 1 9 10.1016/j.jim.2008.01.001 1:CAS:528: DC%2BD1cXktlWku70%3D 18275969
12. S Swanson J Ferbas P Mayeux 2004 Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin Nephron Clin Pract 96 88 95 10.1159/000076746
13. J Lofgren S Dhandapani J Pennucci 2007 Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab J Immunol 178 7467 7472 1:CAS:528:DC%2BD2sXlsVOksb8%3D 17513798
14. D Mytych S La T Barger J Ferbas S Swanson 2009 The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum J Pharm Biomed Anal 49 415 426 10.1016/j.jpba.2008.11.028 1:CAS:528:DC%2BD1MXhs1alsLw%3D 19135328
15. P Safsten 2009 Epitope mapping by surface plasmon resonance Methods Mol Biol 524 67 76 10.1007/978-1-59745-450-6-5 19377937
16. XM Sharon X Min E Gary 1995 Megakaryocyte growth and development factor and interleukin-3 induce patterns of protein-tyrosine phosphorylation that correlate with dominant differentiation over proliferation of mpl-transfected 32D cells Blood 86 4532 4543
17. D Kuter J Bussell R Lyons 2008 Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double- blind randomized controlled trial Lancet 371 395 403 10.1016/S0140-6736(08)60203-2 1:CAS:528: DC%2BD1cXhtl2isL4%3D 18242413
18. J Bussel D Kuter V Pullarkat 2009 Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP Blood 113 2161 2171 10.1182/blood-2008-04-150078 1:CAS:528:DC%2BD1MXjt12nt7g%3D 18981291
19. Y Shirasugi K Ando S Hashino 2009 A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura Int J Hematol 90 157 165 10.1007/s12185-009-0361-y 1:CAS:528:DC%2BD1MXhtVeitbnE 19543952
20. J George S Mathias G RS 2009 Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials Br J Haematol 144 409 415 10.1111/j.1365-2141.2008.07464.x 1:CAS:528:DC%2BD1MXis1Wrsbg%3D 19016720
21. S Swanson 2006 Immunogenicity issues in drug development J Immunotoxicol 3 165 172 10.1080/15476910600908852 1:CAS:528:DC%2BD28XpvFWrs7w%3D 18958697
22. V Broudy N Lin 2004 AMG 531 stimulates megakaryopoiesis in vitro by binding to Mpl Cytokine 25 52 60 10.1016/j.cyto.2003.05.001 1:CAS:528: DC%2BD3sXhtVSju7jN 14693160
23. L Aledort C Hayward M Chen J Nichol J Bussel 2004 Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies Am J Hematol 76 205 213 10.1002/ajh.20104 1:CAS:528:DC%2BD2cXlvFOmtbo%3D 15224353
24. W Fureder U Firbas 2002 Serum thrombopoietin levels and anti-thrombopoietin antibodies in systemic lupus erythematosus Lupus 11 221 226 10.1191/0961203302lu177oa 1:STN:280:DC%2BD38zgt1CjsA%3D%3D 12043885
25. M Oldstone 1998 Molecular mimicry and immune-mediated diseases Faseb J 12 1255 1265 1:CAS:528:DyaK1cXms1Cmsbo%3D 9761770
26. L Albert R Inman 1999 Molecular mimicry and autoimmunity N Engl J Med 34 2068 2074 10.1056/NEJM199912303412707